The dual kinase complex FAK-Src as a promising therapeutic target in cancer by Bolós, Victoria et al.
© 2010 Bolós et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
OncoTargets and Therapy 2010:3 83–97
OncoTargets and Therapy
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
83
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The dual kinase complex FAK-Src as  
a promising therapeutic target in cancer
Victoria Bolós1,* 
Joan Manuel Gasent2,* 
Sara López-Tarruella3 
Enrique Grande1,#
1Pfizer Oncology, Madrid, Spain; 
2Hospital Gral. Universitario Marina 
Alta, Oncology Department, Denia 
Alicante, 3,#Hospital Clínico San 
Carlos, Oncology Department, ∗These 
authors contributed equally to this 
work, #Center affiliated to the Red 
Temática de Investigación Cooperativa 
(RD06/0020/0021). Instituto de Salud 
Carlos III (ISCIII), Spanish Ministry of 
Science and Innovation
Correspondence: M Victoria Bolós
Pfizer Oncology, Avda. de Europa 20B, 
Alcobendas-Madrid, ZIP 28108, Spain
Tel +34 91 490 96 60
Fax +34 91 490 97 51
Email mariavictoria.bolos@pfizer.com
Abstract: Focal adhesion kinase (FAK) and steroid receptor coactivator (Src) are intracellular 
(nonreceptor) tyrosine kinases that physically and functionally interact to promote a variety of 
cellular responses. Plenty of reports have already suggested an additional central role for this 
complex in cancer through its ability to promote proliferation and anoikis resistance in tumor 
cells. An important role for the FAK/Src complex in tumor angiogenesis has also been established. 
Furthermore, FAK and Src have been associated with solid tumor metastasis through their 
ability to promote the epithelial mesenchymal transition. In fact, a strong correlation between 
increased FAK/Src expression/phosphorylation and the invasive phenotype in human tumors has 
been found. Additionally, an association for FAK/Src with resistances to the current anticancer 
therapies has already been established. Currently, novel anticancer agents that target FAK or 
Src are under development in a broad variety of solid tumors. In this article we will review the 
normal cellular functions of the FAK/Src complex as an effector of integrin and/or tyrosine kinase 
receptor signaling. We will also collect data about their role in cancer and we will summarize the 
most recent data from the FAK and Src inhibitors under clinical and preclinical development. 
Furthermore, the association of both these proteins with chemotherapy and hormonal therapy 
resistances, as a rationale for new combined therapeutic approaches with these novel agents, to 
abrogate treatment associated resistances, will also be reviewed.
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The nonreceptor tyrosine kinases FAK and SRC
The FAK-SRC complex in the integrin  
and tyrosine kinase receptor setting
Integrins are a family of transmembrane receptors that link the extracellular matrix 
(ECM) and the intracellular actin-cytoskeleton. These cell-matrix areas of adhesion are 
known as focal adhesion (FA) contacts/areas. Integrins cluster when they bind to ECM. 
Integrin clustering has a structural role but also induces the activation of intracellular 
signaling pathways that lead to important cellular responses such as proliferation, 
survival, migration and invasion in both normal and tumor cells.1 In this setting, the 
linked activities of two nonreceptor intracellular tyrosine kinases, focal adhesion kinase 
(FAK) and steroid receptor coactivator (Src), is a common intracellular point of con-
vergence in the signaling initiated by this integrin-ECM interaction. In response to the 
clustering, FAK associates to the cytoplasmic tail of the integrin and in response to this 
association FAK phosphorylates at its tyrosine residue 397 (Y397). Although this Y397 
phosphorylation is mainly due to autophosphorylation; transphosphorylation by growth 
factors might also occur. This phosphorylated tyrosine provides a docking site for Src 
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(Figure 1).2 The tyrosine kinase Src, then, phosphorylates 
additional sites on FAK, leading to further increased activity 
of FAK and allowing the recruitment of proteins that contain 
Src homology 2 (SH2) domains such as Grb2 and PI3K.3 
The mutually activated FAK/Src complex then initiates a 
cascade of phosphorylation events of new protein–protein 
interactions to trigger several signaling pathways that 
eventually leads to different cellular responses. For instance, 
Grb2, once bound to FAK can recruit SOS into the complex 
and activates the downstream Ras-MAPK pathway and/or 
may also transduces the signal through the activation of the 
PI3K-Akt cascade.3–5
Adhesion is a hallmark of solid cancer cells and integrins 
are a nexus between intracellular signaling and cytoskeletal 
dynamics; besides, integrin-mediated signaling also intersects 
with growth factor-mediated signaling through various levels 
of cross-talk. In this complex network, the FAK/Src complex 
also transduces signals from tyrosine kinase receptors (TKRs) 
or integrates signals from both, integrins and TKRs, (see 
Figure 1) in normal and tumor cells.3,4 As an illustration of 
this connection in breast cancer, transforming growth factor 
β (TGF-β) has recently been found to be able to induce 
membrane-proximal clustering of human EGF (Epidermal 
Growth Factor) receptor 2, (HER2) and integrins by activating 
Src-FAK and receptor association to the cytoskeleton.6
Platelet-derived growth factor receptor (PDGF-R), 
epidermal growth factor receptor (EGF-R), fibroblast 
growth factor receptor (FGF-R), insulin-like growth factor-
1 receptor (IGF-1R), hepatocyte growth factor (HGF-R), 
colony-stimulating factor-1 receptor (CSF-1R) or, stem cell 
factor receptor (SCF-R) are also TKRs that may transduce 
their signal by FAK/Src activation. As a consequence, the 
FAK/Src complex is potentially involved in different steps of 
tumorogenesis and further growth and metastatic progression 
of malignant tumors.7,8
The increased expression or activity of FAK and/or Src 
in tumors is associated with a more invasive and aggres-
sive phenotype and has lead to the development of Src and 
FAK inhibitors as new anticancer drugs.9–12 These drugs are 
able to block proliferation, survival, angiogenesis and/or 
migration/invasion in preclinical tumor models13 and some 
of them have already shown preliminary antitumor activity 
in clinical trials with cancer patients.14–19
FAK and Src structure
c-Src was the first characterized human oncogene. In 1909 
Peyton Rous identified the Rous Sarcoma’s Virus (RSV).20,21 
Later, in 1958, the v-Src gene was identified as the cause 
that allowed RSV to produce the sarcoma when the virus 
infected healthy chickens. The v-Src gene was taken up 
by RSV and incorporated into its genome conferring the 
virus the advantage of being able to stimulate uncontrolled 
proliferation in host chicken cells. Finally the human 
homologue of the v-Src gene, c-Src, was characterized as 
the first oncogene in humans.22
c-Src is a nonreceptor tyrosine kinase. The Src family 
comprises of eight members in humans (Src, Fyn, Yes, Lyn, 
Lck, Hck, Blk and Fgr) with a molecular weight between 
52–62 KDa.22,23 Each Src kinase family member is comprised 
of six domains. A SH4 domain placed at the N-terminal tail is 
involved in targeting Src to the plasmatic membrane. Adjacent 
to the SH4 domain, a region that is specific to each Src fam-
ily member followed by a SH3 and a SH2 domain, both of 
them involved in the interaction of Src with other intracellular 
proteins (Figure 2).23 Additionally, in the C-terminal tail, there 
is an SH1 domain involved in adenosine tri-phosphate (ATP) 
and substrate binding. This SH1 domain shows tyrosine kinase 
activity. The phosphorylation in the Y419 residue of the SH1 
domain is required for maximum kinase activity. Immediately 
adjacent to the SH1 domain, there is another C-terminal 
region that acts as a negative regulatory domain that is itself 
regulated by phosphorylation. After phosphorylation of the 
Y530 residue, placed in this negative regulatory domain, Src 
undergoes conformational changes and becomes inactive.23 
Src activation is regulated at many different levels. In response 
to a signal stimuli Src translocates from the cytosol to the 
membrane where it will be activated by phosphorylation, the 
intracellular localization of Src is therefore one of the key 
regulatory mechanisms that control Src activation.24 In addi-
tion the binding of FAK to the SH2 domain of Src relieves 
its autoinhibitory interaction that leads to the activation of 
Src. Once activated, Src phosphorylates FAK on a number 
of additional tyrosine residues, leading to further increased 
activity of FAK.2,23,25 In this sense, FAK acts as a molecular 
scaffold protein to activate and recruit Src to its substrates.
FAK was first identified in the search for proteins that 
where tyrosine phosphorylated in an integrin dependent 
manner and also in Src transformed fibroblasts as a key 
substrate of Src oncoprotein.26 It was described as a focal 
adhesion-associated nonreceptor protein tyrosine kinase27,28 
ubiquitously expressed and encoded by an evolutionarily 
highly conserved gene.
FAK harbors a central region with kinase activity that 
is flanked by a large N-terminal region that contains the 
erythrocyte band four 1-ezrin-radixin-moesin (FERM) domain 
and by a C-terminal region that contains the focal adhesion OncoTargets and Therapy 2010:3 85
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Figure 1 FAK/Src complex mediated signaling pathway. 
Notes: The FAK/Src complex transduces signals from a variety of membrane receptors such as tyrosine kinase repectors and integrins through the activation of intracellular 
signaling pathways such as PI3K-AKt and Ras-MAPK to reach a cellular response. 
Abbreviations: ERK, extracellular signal regulated kinase; FA, focal adhesions; MEK, mitogen-activated protein; FAK, focal adhesion kinase; VEGF, vascular endothelial growth 
factor; MMPs, matrix metalloproteinases.
targeting (FAT) domain. The Y397 residue, immediately adja-
cent to the kinase domain, is autophosphorylated in response 
to the clustering of integrins. This autophosphorylation 
increases the catalytic activity of FAK and creates a high 
affinity binding site for the SH2 domain of Src. This 
interaction recruits and activates Src. The formation of the 
complex with Src is the most critical event in FAK-associated 
signaling. Src binds the Y397 residue and phosphorylates 
other FAK residues including Y576 and Y577 placed on the 
catalytic loop of the kinase and Y861 that are important for OncoTargets and Therapy 2010:3 86
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full catalytic activity of FAK. Y925 has been also identi-
fied as an important site for phosphorylation by Src, which 
involves Src in induced epithelial mesenchymal transitions 
(EMTs).29,30 In the absence of stimuli from integrins and/or 
TKRs, the FERM domain works as a negative regulator of 
FAK activity. This domain interacts with the kinase domain 
preventing Y397 phosphorylation. Conversely, in response 
to co-clusters of integrins and TKRs, the FERM domain 
interacts with the cytoplasmic tail of the integrin allowing 
FAK-autophosphorylation in this Y397 residue. The FAT 
domain, placed in the C-terminal region, mediates the co-
localization of FAK with the FA areas through the interaction 
of FAK with the FA associated proteins talin and paxillin. 
Furthermore, two proline rich domains, placed adjacent to 
the FAT domain, mediate the interaction of FAK with SH3 
containing proteins such as p130CAS.9,11 The ability of FAK 
to promote the activation of p130CAS depends on Src activ-
ity. Although the scaffold function of FAK to recruit Src to 
its substrates is has already been well established, however 
less is known regarding FAK kinase activity.
Besides integrins, the N-terminal region of FAK also 
interacts with TKRs, and this interaction may be involved in 
the regulation of FAK activity and in addition in cross-talks 
between integrins and TKRs.31 Phosphorylation of FAK.
Y861 promotes association of FAK with the αyβ5 integ-
rin following vascular endothelial growth factor (VEGF) 
stimulation.32
Different FAK isoforms from alternative splicing have 
been found: FAK, proline rich tyrosine kinase 2 (PYK2) and 
FAK related nonkinase (FRNK).9 FRNK lacks the catalytic 
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Figure 2 FAK and Src structure.
Notes: A) FAK structure. FAK harbors a central region with kinase activity that is flanked by a N-terminal region that contains the FERM domain and by a C-terminal region 
that contains the FAT domain. The autophosphorylation in its Y397 residue increases its catalytic kinase activity and allows the binding of specific intracellular proteins. FAK 
is phosphorylated by Src in its Y576 and Y577 residues allowing its full catalytic activity. In absence of stimulus, the FERM domain works as a negative regulator of FAK activity 
through its interaction with the kinase domain preventing the phosphorylation in Y397. In response of stimuli, the FERM domain interacts with the cytoplasmic tail of the 
integrins. Allowing the autophosphorylation of FAK in this tyrosine. The FAT domain, placed in the C-terminal region, mediates the co-localization of FAK with the FA areas 
through the interaction of FAK with the FA associated proteins talin and paxillin. Two proline-rich domains (PR) mediate the interaction of FAK with SH3 containing proteins 
such as p130 CAS. B) Src structure. Src is comprised of six domains: a SH4 involved in targeting Src to the plasmatic membrane, a region U that is specific of each Src family 
member, a SH3 and a SH2 domain involved in the interaction of Src with other intracellular proteins and a SH1 domain involved in ATP and substrate binding. The phosphorylation 
in Y419 residue of the SH1 domain is required for maximum kinase activity. Placed immediately adjacent to the SH1 domain there is a negative regulatory domain. After 
  phosphorylation of the Y530 residue, in the negative regulatory domain, Src becomes inactive.
Abbreviations: FAK, focal adhesion protein; RTK, tyrosine kinase receptor; FERM, Band 4.1 Ezrin, Radixin, Moesin; PI3K, phosphoinositide 3 kinase.OncoTargets and Therapy 2010:3 87
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domain working as a FAK inhibitor competing with nontrun-
cated endogenous FAK for the localization at FA areas.33
FAK activity is under strict regulation by a variety of 
kinases and phosphatases such as glycogen synthetase kinase 
3 type β (GSK3 β), tyrosine phosphatase SHP-2, serine/
threonine protein phosphatase type 1 as well as by Src.9,34,35
FAK and Src and their function  
in normal and tumor cells
Although, most available articles in the literature show 
FAK and Src as independent proteins, the current idea that 
both proteins work as a protein complex in the cellular 
signaling networks is emerging. FAK would form a binary 
complex with Src family kinases which can phosphorylate 
other substrates and trigger multiple intracellular signaling 
pathways that would induce different cellular responses.
FAK and Src are not only critical modulators of signaling 
pathways mediated by TKRs and integrins, they also respond 
to stimuli from G protein-coupled receptors, cell–cell 
adhesion proteins (ie, cadherins) and steroid hormone 
receptors to control a variety of normal and oncogenic 
cellular responses such as cell survival, proliferation and 
migration/invasion.4,22,23,34,36,37
FAK-null embryos exhibit an early embryonic lethal 
phenotype.38 These embryos show multiple defects, including 
a disorganized cardiovascular system due to extensive defects 
in angiogenesis and vasculogenesis.38 Accordingly, over 
expression of FAK in vascular endothelial cells promotes 
angiogenesis.39 In addition, conditional deletion of FAK 
in adult mouse epithelium was not lethal, and probably 
due to a functional compensatory effect mediated by its 
related family member PYK2.40 Although PYK2 knock out 
mice develop normally except they do exhibit defective 
macrophage migration.41,42 The above data suggested that 
endothelial cells may posses an adaptive capacity to switch 
to PYK2 dependant signaling after deletion or inhibition 
of FAK. Thus, FAK and PYK2 inhibition may result in an 
antiangiogenic effect.
An interesting interaction has also been reported between 
FAK and the tumor suppressor protein p53, via the FERM 
domain that triggers p53 degradation, so that loss of FAK 
results in activation of p53 which could eventually suggest new 
approaches to trigger cytotoxic drug induced apoptosis.43
Although, Src-null mice were viable, the analysis of 
homozygous mutants showed that they were deficient in 
bone remodeling (they had an impaired osteoclast function) 
and also developed osteopetrosis. This phenotype demon-
strated that Src is not required for general cell viability 
possibly due to a Src functional overlap with other related 
tyrosine kinases such as FAK. Therefore, Src may play 
an essential role in bone formation.44 Accordingly, cancer 
patients treated with a Src inhibitor showed reduced serum 
levels of bone resorption markers suggesting Src inhibi-
tors as a possible effective treatment for established bone 
metastasis.45,46
In normal adult tissues and tumor cells, FAK and Src 
control many important biological processes within the cell. 
They have been associated with responses of cell growth 
and survival.9,10 In addition, they have also been involved 
in anoikis (apoptosis induced when anchorage-dependent 
cells detach from the surrounding ECM) resistance in 
tumor cells.47–50 Hence, FAK/Src activation may promote 
the anchorage-independent growth/transformation of tumor 
cells through the inhibition of the apoptotic response.48,49 
FAK activation, in response to integrins, has an important 
role in FA turnover/rearrangement. This process is crucial 
for cell spreading and migration in physiological and 
pathological processes (ie, FA turnover is essential for 
EMTs during the metastatic behavior of tumor cells and 
in endothelial cell migration during tumor angiogenesis).9 
Phosphorylation of FAK-Y925 is the major Src-specific 
phosphorylation event that is associated with integrin 
adhesion dynamics and E-cadherin deregulation during 
Src-induced EMT.29,30
Furthermore, FAK has already been found, at elevated 
levels, in the majority of human cancers (head and neck, 
colon, breast, prostate, liver, thyroid, and others), particularly 
in highly invasive metastases.51 High levels of Phospho-FAK 
Y397 has already been found in: ovarian invasive tumors;52 
acute myeloid leukemia;53 squamous cell carcinoma of the 
laryn;54 invasive cervical carcinoma;55 invasive human colon 
cancer cells;56 medullary thyroid cancer cell lines;57,58 human 
pancreatic cancer cells;59 glioma cells;60 and other tumor 
types. Furthermore, high levels of FAK phosphorylated in 
other tyrosine residues have already been found in specific 
tumor types. Papillary thyroid cancer samples show high phos-
phor-Y861-FAK levels and high levels of phopho-Y861-FAK 
have also been correlated with sensitivity to the Src inhibitor 
AZD0530 in papillary and also in anaplastic thyroid cancer 
models.61 Although, the relationship between Src and cancer 
progression is best documented in colon and breast cancer.10,62 
Src over expression or over activation has also been shown in 
a variety of human biopsies from primary tumors and their 
metastases (Figure 3).23
An additional pro-angiogenic role for FAK and Src 
signaling in tumors has also been suggested.63–69 FAK OncoTargets and Therapy 2010:3 88
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expression has been found in tumor endothelial cells 
from grade III and IV astrocytoma biopsies; whereas FAK 
expression was absent in endothelial cells of normal brain 
biopsies.63 Accordingly, tumor endothelial cells transfected 
with FRNK (a negative FAK regulator) showed less 
migration in vitro than control cells; suggesting that FAK is 
involved in tumor-angiogenesis, at least in part, through the 
induction of endothelial cell migration.63 Preclinical data 
from prostate cancer cell lines have also suggested a role 
for FAK signaling in the induction of VEGF expression 
in tumor cells.70 Additionally, an intracellular cross-talk 
between the Ang-1 TKR (Tie-2) involved in angiogenesis 
in tumors and integrin pathways has also been shown.71 
The binding of integrin α1β5 to ECM-glycoproteins may 
lead to the association of Tie-2 with integrin α1β. The 
stimulation of Tie-2 by Ang-1 may promote the recruitment 
of FAK to the TKR-integrin areas inducing an endothelial 
cell response (sprouting and stabilization of the new tumor 
vessels).71 Src has also been associated with VEGF pro-
duction in tumor cells.66 In fact, Src inhibition decreases 
angiogenesis in vivo.68,69
Immunohistological data about the expression/correla-
tion between active FAK/Src on primary tumors and on their 
metastases is still awaited, to explore the value of FAK/Src 
as predictors of tumor outcome.
In fact, as we will review below, a link for FAK/Src 
with chemoresistance has already been reported in tumor 
models. In fact, FAK downregulation enhances docetaxel 
cytotoxicity in ovarian cancer cells.72 Moreover, FAK 
downregulation also increases gemcitabine chemosensi-
tivity in pancreatic cancer cells.73 Accordingly, a variety 
of reports show a role for Src in the promotion of chemo-
resistance.74–77 Src inhibitors have already shown single 
agent activity in cancer patients after their progression to 
chemotherapy.78 Src inhibition promotes chemosensitivity 
in pancreatic cancer cells.74 In addition, a combination of 
5-fluorouracil (5-FU) and a Src inhibitor in 5-FU-resistant 
human pancreatic cancer cell lines restored 5-FU-induced 
apoptosis.74 The potential mechanism for 5-FU chemosen-
sitivity induced by Src inhibitors might be associated with 
the inhibition of the epidermal growth factor receptor-AKT 
(EGFR–AKT) pro-survival pathway induced by 5-FU. Fur-
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Figure 3 Role of the FAK-Src complex in the malignant progression of solid tumors.
Notes: FAK and Src play a critical role in solid tumor progression mainly through its ability to promote the epithelial-mesenchymal transition associated with the metastatic 
behavior of solid tumors.
Abbreviations: ECM, extracellular matrix; EMT, epithelial mesenchynal transitions; FAK, focal adhesion kinase; Src, steroid receptor coactivator.OncoTargets and Therapy 2010:3 89
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thermore, a role for Src in mediating acquired endocrine 
resistance is also well established.10
Other FAK family members have also been associated 
with cancer. In fact, Pyk2 also shows a high expression 
and an association with tumor progression in a variety of 
tumor types such as: astrocytomas; breast; glioma; prostate; 
hepatocarcinoma; and nonsmall cell lung cancer.79–83 In 
addition, other Src family members have also been associated 
with solid and hematological tumors; and inhibitors against 
Src family members are under development as new anticancer 
drugs.84
FAK-Src and tumor associated 
epithelial mesenchymal transition
Epithelial mesenchymal transition (EMT) is a complex of 
cellular and molecular processes by which epithelial cells 
acquire mesenchymal and migratory properties.85 EMT takes 
place during critical phases of embryonic development and 
is also a crucial step in the infiltration and progression in 
solid tumors. Hallmarks of EMT include loss of cell–cell 
contacts, induction of FA turnover and increased expression 
of mesenchymal (fibronectin, vimentin, N-cadherin, 
α-smooth muscle actin, and others) and invasiveness 
(ie, metalloproteinases) markers.86 The EMT is at the 
convergence of different molecular pathways involving cell 
survival and resistance to apoptosis, invasion and tumor 
angiogenesis, metastasis and drug resistance in advanced 
tumors.87
A critical molecular feature in the loss of cell–cell 
contacts during EMT is the downregulation of the adhesion 
molecule E-cadherin (delocalization/loss of E-cadherin 
expression). A variety of membrane receptors such as 
integrins, TKRs, serine-threonine kinase receptors are able 
to induce E-cadherin downregulation during development 
and tumor progression through the activation of specific 
intracellular signaling cascades such as Ras-MAPK and 
PI3K-Akt-mTOR. In fact, transcriptional repressors 
(Snail, Slug, Twist, or ZEB1/2) involved in EMTs during 
development are also induced in response to EMT stimuli 
to repress E-cadherin expression during tumor progres-
sion.86 Plenty of evidence suggests that FAK and Src, 
through its ability to integrate signals from numerous sig-
naling receptors, plays a critical role in tumor-associated 
EMTs promoting intracellular signaling pathways that 
lead to the induction of E-cadherin repressors and to the 
subsequent E-cadherin downregulation as well as that pro-
mote FA turnover to allow tumor cell migration/invasion 
(Figure 1B).88–91
New anticancer drugs that  
target FAK and Src
Based on evidence that supports FAK as a molecular scaffold 
protein, activated by Src to recruit its substrates; and that Src, as 
a tyrosine kinase is involved in the catalytic activation of FAK, 
and triggers FAK kinase activity to promote a variety of cellular 
responses during tumor progression, preclinical and clinical 
studies with new agents that employ different mechanisms for 
the blockade of FAK or Src kinases are currently underway.9,10 
We show below a summary of the most advanced FAK and 
Src inhibitors under development (see Table 1).
Historically the first drugs synthesized with the aim of 
inhibiting T-cell activation via the Src family kinases Lck and 
Fyn were PP1 and PP2. The latest one is very selective for 
Src family kinases (SFKs). After PD173955 and PD173956 
emerged with a lower selectivity than that of PP2, since these 
compounds were inhibitors of; Abl, Csk, platelet derived 
growth factor receptor (PDGFR) and EGFR. CGP76030 
and CGP77675 were also multi-targeted agents against 
SFKs, Abl, EGFR and VEGF receptor (VEGFR) and SFKs, 
EGFR, FAK, and VEGFR, respectively. A third generation of 
molecules characterized by their higher potency in enzyme 
assays and their dual inhibition of c-Abl in a variety of ima-
tinib-resistant c-Abl mutations appeared. The strong activity 
against c-Abl together with the potent anti-Src activity is 
explained by the strong structural similarity of the ATP bind-
ing domains in both kinases. The dual selectivity speeded up 
the development of these compounds.
At present, researchers are strongly focused on the 
study of the potential therapeutic benefits from the use of 
ATP-competitive kinase inhibitors against FAK and Src. 
These inhibitors interact with the ATP-binding pocket 
of FAK or Src and subsequently prevent FAK and Src 
autophosphorylation and therefore their activation.11
Dasatinib
Dasatinib (BMS-354825) is an orally active small multiselective 
inhibitor, which inhibits the kinases Src and Abl with IC50 val-
ues of 0.55 and 3.0 nM, respectively.92 Dasatinib also inhibits 
other Src family members such as Fyn (half maximal inhibitory 
concentration [IC50] of 0.2 nM), LcK (IC50 of 1.1 nM) and 
Yes (IC50 of 0.4 nM).92 Dasatinib blocks the wild type chimeric 
Bcr-Abl protein which arise from Philadelphia chromosome.93 
Dasatinib is a 20-fold more potent inhibitor than imatinib 
in cells expressing wild-type Bcr–Abl hybrid protein and it 
also has an antitumoral effect in those tumor cells express-
ing Bcr–Abl imatinib-resistant mutants.93 Dasatinib is also 
able to inhibit the tyrosine kinase receptors c-KIT, PDGFR-β OncoTargets and Therapy 2010:3 90
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and ephrins (EPHA2).92 Dasatinib has already shown to have 
broad preclinical activity in solid and hematological tumor 
models.14,92 It has already been approved by the Food and Drug 
Administration (FDA) and by the European Medicines Agency 
(EMEA) for the second line treatment of imatinib-refractory 
chronic myelogenous leukemia (CML) and Philadelphia 
chromosome-positive acute lymphoblastic leukemia (ALL).14 
Currently, phase I/II clinical trials with dasatinib as a single 
agent or in combination are underway in a variety of solid and 
hematological tumors, based on the capability of dasatinib for 
blocking the activity Src family members.94 Besides effective-
ness in hematologic malignancies, dasatinib can suppress 
tumor growth in human breast cancer, human prostate, colon, 
ovarian, and lung cancer lines.95–100
AZD0530
AZD0530 is another novel, orally administered, potent, 
and highly selective inhibitor of Src (IC50 value  4 nM), 
other Src family members like LcK and Yes (both with 
IC50 values  4 nM) and Abl as well.101 Preclinical activity 
has been shown in: skin; breast; prostate; and pancreatic 
tumor models101 as well as estrogen receptor-positive breast 
cancer models102 where the combination of AZD0530 with 
tamoxifen103 and aromatase inhibitors104 prevented hormonal 
therapy resistance. This combination also shows an additive 
effect of delaying the growth of breast cancer cells.105
A variety of phase I and II clinical trials are currently 
underway with AZD0530 in monotherapy or in combina-
tion, in patients with solid tumors based on its capability to 
inhibit Src.106 Another possible use of AZD0530 has been 
recently reported. Based upon the hypothesis that Src could 
be involved in the development of metastases in xenograft 
modes where the growth of the primary tumor was controlled 
by radiation; this report shows that those tumors from mice 
receiving AZD0530 regress more quickly following radio-
therapy than their control counterparts.107
Bosutinib 
Bosutinib (SKI-606) is a potent, orally administered, 
bioavailable, dual Src (IC50 value of 3.8 nM) and Abl inhibitor 
which has already shown to have an antitumoral effect in 
chronic myelocytic leukemia (CML), colon, prostate and 
breast cancer models.108,109 Preclinical breast cancer models 
showed a decrease in in vitro cell motility and invasion and 
in vivo metastases after bosutinib treatment.110 A phase I 
clinical trial with bosutinib has been published showing; drug-
related dose-limiting toxicity of grade 3 diarrhea and grade 
3 rash (1 pt) with 400 mg being selected as the maximum 
tolerated dose.111 Currently, phase II, proof of concept clinical 
trials, in patients with CML who had failed to improve with 
Imatinib, and in patients with solid tumors, are underway.112
PF-562,271
PF-562,271 is a potent ATP-competitive, small molecule 
inhibitor of both FAK and the related kinase Pyk2 (IC50 values 
of 1.5 nM (0.7 ng/mL) and 14 nM (7 ng/mL), respectively). 
Table 1 Summary of FAK and Src inhibitors under clinical and preclinical development
Drug Target  
(IC50)
IC50 IC50 IC50 Preclinical activity Clinical activity
Src FAK Abl IGF1R
BMS-354825 
(Dasatinib)
0.55 nM 3.0 nM Solid and hematological  
tumor models
Approved in Imatinib  
  refractory CML and  
Philadelphia chromosome + ALL, 
Phase 1–2 clinical trials in  
solid and hematological tumors 
are underway
PF-562,271 797 nM 1.5 nM  
(0.7 ng/mL)
500 nM Colon, breast, prostate,  
pancreatic and lung tumor  
models
Phase 1 clinical trial in solid  
tumors has been already  
communicated
TAE-226 100 nM/L  
= 100 nM
300 nM/L  
= 300 nM
Glioma and human  
pancreatic tumor cell lines
Not yet
AZD0530 4 nM  
27 nM
Skin, prostate, breast  
and pancreatic tumor models
Phase 1–2 clinical trial  
underway
SKI-606  
(Bosutinib)
3.8 nM CML, colon and breast models Phase 1 clinical trial has been  
already communicated, Ph II 
  clinical trial in CML patients  
after imatinib failure under  
development
Abbreviations: FAK, focal adhesion kinase; CML, chronic myelogenous leukemia; IGF, insulin-like growth factor; IC, inhibitory concentration.OncoTargets and Therapy 2010:3 91
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PF-00562271 also inhibits other kinases such as c-Src and 
insulin growth factor 1 receptor (IGF1R) with less selectivity 
(IC50 value of 797 nM and IC50  500 nM respectively). 
This inhibitor has shown a broad preclinical activity.113 In 
PC3 human prostate tumor cells, PF-00562271 treatment 
blocks, anchorage independent tumor cell growth and tumor 
cell migration in vitro, has shown antitumoral effects in vivo.11 
PF-00562271 decreases FAK phosphorylation-status in vitro 
and shows antitumor efficacy in vivo, in xenografts from: 
human colon; breast; prostate; pancreatic; and hepatocellular 
carcinoma tumor cell lines.113–115 No weight loss, or increase in 
morbidity and mortality were observed in any in vivo experi-
ment and tumor growth inhibition was dose and drug exposure 
dependent. Furthermore, PF-562271 also showed an additional 
antiangiogenic effect over tumors.113 PF-562271 through the 
inhibition of FAK and PYK2 kinases may interfere with the 
ability of endothelial tumor cells to migrate, thus blocking 
the sprouting and stabilization of the new tumor vessels.63,116 
PF-00562271 treatment has also led to the blockade of the 
expression of pro-angiogenic growth factors in tumor cells, 
such as VEGF.70 Recently, Bagi and colleagues showed that 
PF-00562271 synergized with antiangiogenic agents that 
directly block VEGF signaling, through its ability to target 
different aspects of angiogenesis and tumor aggressiveness.115 
In addition, these authors show that the combination of these 
agents not only led to the blockade of tumor growth, it also 
impacted upon the ability of the tumor to recover on withdrawal 
of the therapy. PF-562,271 has also showed an in vivo effect 
in preventing the loss of bone, suggesting its potential activ-
ity in patients with bone metastases and cancer-associated 
osteoporosis.117 Therefore, PF-562,271 may comprise of a 
combined action over tumors: antiproliferative; proapoptotic; 
antiangiogenic; and antimetastatic action. Based on the 
preclinical data, a dose escalation phase 1 clinical trial with 
PF-562,271, administered orally as a single agent, in patients 
with solid tumors is currently underway. Tumor responses 
with PF-562,271 have been already reached in ovarian, colon 
together with head and neck cancer patients. Preliminary 
results showed a manageable safety profile with PF-562,271. 
In addition, continuous oral dosing is feasible and may be 
extended over 6 to 12 months in the majority of patients. The 
most common adverse events in the 32 evaluated patients with 
monitored safety data was: nausea in 14 patients (Grade 3); 
vomiting in 12 patients (only 1 patient with Grade 3); fatigue 
in 8 patients (Grade 3); and diarrhea in 6 patients (Grade 
3). Prolonged disease stabilization has already been observed 
in a variety of solid tumors. However, the maximum tolerated 
dose (MTD) and recommended Phase 2 dose have still to be 
published.15,16 In addition to PF 573,228, a closely related, early 
prototype FAK inhibitor118 has been reported to have appealing 
activity in combating ovarian cancer metastases,119,120 demon-
strating the growing body of evidence that supporting research 
of Src/FAK inhibitors in epithelial carcinoma.
TAE 226
TAE 226 is a low molecular weight, ATP-competitive tyro-
sine kinase inhibitor of FAK and IGF1R with an IC50 range 
of 100 to 300 nM/L.121 TAE 226 is still under preclinical 
development. Flow cytometry analysis of human glioma cell 
lines under TAE 226 treatment have shown an increase in 
the apoptotic and G0 (quiescent/nonproliferative) fractions 
after treatment, when these cells were compared with control/
nontreated cells.60 TAE 226 induced-apoptosis in the glioma 
tumor model is mediated by caspases and is correlated with 
the p53 status. In fact, apoptosis was only induced in the subset 
of glioma cell lines containing the mutant p53 gene.60
Additionally, TAE 226 treatment also prevented the in vitro 
attachment of these glioma cell lines. Furthermore, an in vivo 
intracranial glioma xenograft model showed a significantly 
higher median survival in the group of mice treated with 
TAE 226, at concentrations of 50–75 mg/kg. The treatment of 
ovarian cancer cell lines with TAE 226 inhibited cell growth 
in both a time- and dose-dependent manner; and enhanced 
docetaxel-mediated growth inhibition by 10 and 20 fold in the 
taxane-sensitive and taxane-resistant ovarian cell lines, respec-
tively. In addition, TAE 226 alone and in combination with 
chemotherapy significantly prolonged survival in tumor-bearing 
mice. The efficacy of TAE 226 was related to: reduced peri-
cyte coverage; the induction of apoptosis of tumor-associated 
endothelial cells; reduced microvessel density and tumor cell 
proliferation.121 TAE 226 also displayed an antitumoral effect 
in human pancreatic cell lines,122 esophageal cancer cell lines 
and xenografts, by a potent inhibition of PI3K-AKT-mTOR cell 
survival signaling.123 Clinical trials with this new dual FAK-
IGF1R inhibitor are planned. Recently, interesting experiments 
have suggested that the FAK–IGF–1R interaction site could be 
targeted; the specific disruption of this protein–protein interac-
tion with another small molecule inhibitor (INT2-31) reinforces 
the potential novel role of this antineoplastic strategy.124
FAK/Src and chemotherapy 
resistance
As we mentioned above, an association between FAK 
activation and resistance to chemotherapy has been broadly 
reported in human tumor models.72,73,125–128 Accordingly, the 
combination of conventional chemotherapeutic drugs with OncoTargets and Therapy 2010:3 92
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FAK-targeting agents apparently offers greater efficacy in 
preclinical models than chemotherapy as a single agent. 
Treatment with FAK antisense oligonucleotides significantly 
induced apoptosis in human glioblastoma cells associated 
with a decrease in FAK protein levels.129 The in vitro cytotoxic 
effect achieved with the anti-FAK agent in monotherapy 
was almost the same as those obtained with different 
chemotherapeutic regimens such as cisplatin, etoposide 
and nimustine hydrochloride.129 When FAK antisense 
oligonucleotides and chemotherapy were administered in 
combination the antitumoral effect was clearly additive.129 
Treatment of squamous cell carcinoma models with recom-
binant FRNK peptides combined with etoposide, paclitaxel 
or 5-FU also showed an additive antitumoral effect.127
The effect of combined chemotherapy and anti-FAK agents 
were also explored in human HCC cells in vitro.130 When TNF-
α plus cycloheximide was combined with FAK-antisense, an 
increase in the apoptotic index was observed.130 Additionally, 
FAK siRNA was also able to potentiate gemcitabine action 
in pancreatic cancer cells73 increasing the apoptotic index. 
The in vivo treatment with FAK siRNA, in combination with 
gemcitabine, induced in a statistically significant manner, a 
larger inhibition in the size of the tumors than gemcitabine 
in monotherapy.73 FAK siRNA incorporated in liposomes 
was administered to mice bearing tumors from human ovar-
ian cancer cells.131 Mice treated with siRNA-DOPC showed 
a decrease in tumor weight. Docetaxel in combination with 
siRNA-DOPC resulted in an even greater reduction in tumor 
weight.131 This combination also showed: antiangiogenic 
properties;131 it decreased microvessel density; VEGF and 
MMP-9 secretion; and increased apoptosis in tumor cells, in 
addition to tumor-associated endothelial cells.131 Treatment 
with siRNA-DOPC resulted in a decrease in the tumor weight 
of cisplatin-resistant xenografts as well.131 These data sug-
gest that the combination of anti-FAK agents with docetaxel 
or cisplatin may be a valuable therapeutic approach in the 
chemotherapy of resistant ovarian cancer. Smith and colleagues 
showed that FAK downregulation enhanced the effects of 5-FU 
in human melanoma cells.132 FAK antisense oligonucleotides 
significantly increased cell detachment and apoptosis when 
they were administered alone or in combination with 5 FU.132 
This led to the decrease in FAK protein levels, an effect that 
was also observed with the 5-FU alone. Accordingly, FAK 
blockade plus 5-FU showed and additive effect.
There are also, preclinical data supporting the role of 
Src in chemoresistance. The inhibition of Src reversed 
chemoresistance toward 5-FU in human pancreatic carcinoma 
cells.74 Furthermore, Src inhibition also impaired both inherent 
and acquired gemcitabine resistance in human pancreatic 
adenocarcinoma cells.75 The combination of dasatinib and 
chemotherapy (5′-5′-DFUR or cisplatin) was synergistic in 
triple-negative breast cancer cells.99 In addition, phase 1 clini-
cal trials are currently ongoing, with the Src inhibitor dasatinib 
in combination with chemotherapy in solid tumors.94,133
Interestingly the combination of paclitaxel/carbolatin 
standard chemotherapy in ovarian cancer has shown 
interesting synergism from this combined approach at the 
cell line level, that requires further investigation.134
In conclusion, current evidence shows that FAK/
Src-targeting compounds enhance the action of conventional 
anticancer agents at least in preclinical tumor models. 
Nonetheless, further molecular studies testing the activation 
status of both kinases in tumor biopsies and clinical trials, 
with anti-FAK/anti-Src agents and different chemotherapeutic 
schedules are still required to confirm if this complex is 
involved in treatment resistance and if the combination can 
enhance the efficacy of conventional chemotherapy in the 
clinical setting.
The interest of targeting FAK  
and Src in breast cancer
The Src/FAK signaling pathway is related to multiple receptor 
tyrosine kinases (RTKs) and intracellular mediators with a 
prominent role in the biology of the different subtypes of 
breast cancer.135
On one hand, c-Src interacts with and contributes to the 
signaling cascade of different RTKs; modulates their turnover 
by interfering in the endocytosis; and ubiquitination; in to 
taking part in the cytoskeleton rearrangement, migration and 
survival processes started at the RTKs’ level in tumor cells.7 
In breast cancer there is evidence of the interaction between 
c-Src and EGFR, (although short of a synergistic activity), 
connected to the crosstalk between estrogen receptor (ER) 
and EGFR.136,137 HER2 is coexpressed with c-Src in breast 
cancer138 and their interaction seems to facilitate the migratory 
and metastatic phenotype of these cells.139,140 Likewise, HER2 
is actually involved in c-Src regulation,140 another mechanism 
of activation of HER2 such as the transactivation through 
G-protein receptors (ie, CXCR4).141 C-Src has also been 
proposed to be involved in the modulation of HER2–HER3 
heterocomplexes in an intracellular mediated pattern.142
However, Src has also been linked to the endoplasmic 
reticulum (ER) nongenomic activity143 and the homeostasis 
of the ER144 in the tumor cells.
Src inhibitors have been developed in different breast 
cancer subtypes. Triple negative breast cancer has emerged OncoTargets and Therapy 2010:3 93
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as a potential field to be explored by this family of drugs. 
Two independent groups have described genetic profiles 
associated with a response to dasatinib95,145 highlighting 
the particular sensitivity of the basal-like phenotype to 
this Src inhibitor. This molecular marker approach has led 
to a phase 2 trial in the clinical setting146 showing modest, 
although encouraging, results to be tested in further trials, 
in combination with chemotherapy.
Hormone receptor-positive breast cancer, resistant to the 
classic endocrine therapy strategies, has become another 
field actively studied. In the tamoxifen resistance setting, the 
upregulation of different RTKs’ signaling pathways has been 
involved. It has been suggested that the resistant phenotype 
is not just the result of an estrogen independent growth,147 
but is also linked to an alteration in the relationship between 
the cells and the extracellular matrix, so that these tumor 
cells acquire an invasive and migratory phenotype148,102 that 
favors tumor dissemination. It has been demonstrated that 
anti-HER2 therapies are able to eliminate the agonist effect 
of tamoxifen, restoring its antitumoral capacity149 and the 
blockade of both pathways, showing an increased efficacy 
against endocrine-resistant tumors.100,150,151
However, these combinations have not shown a definitive 
effect regarding the migratory and invasive phenotype,148 
moreover, the tumoral cells eventually develop double 
resistance that results in an even more invasive behavioral pat-
tern.102,152 This dual resistant phenotype is characterized by an 
increase Src kinase activity, that defines another opportunity 
to target endocrine resistant breast cancer. The in vitro utility 
of Src inhibitors; due to the Src/FAK relationship in the acqui-
sition of endocrine resistance in breast cancer, has already 
been tested.153–156 However, a recent article showed an oppo-
site role for Src in breast cancer. Campbell and colleagues 
analyzed 262 breast cancer specimens, before tamoxifen 
treatment, for active Src expression by tissue microarray. 
The authors showed that phosphorylated c-Src in the nucleus 
was significantly associated with improved patient outcome 
in ER-positive breast cancer.157 The current findings suggest 
a crosstalk between ER and Src/FAK kinases, so that the addi-
tion of agents that block Src and/or FAK to hormonal therapy 
may improve the efficacy of the current endocrine therapies 
(aromatase inhibitors and tamoxifen). Clinical trials in breast 
cancer patients with dasatinib and aromatase inhibitors are 
underway in breast cancer patients.94
Conclusions
As we reviewed above FAK and Src form a mutually 
activated complex that acts as a common intracellular point 
of convergence in the signaling initiated by a variety of 
membrane receptors (RTKs, Integrins, G-coupled recep-
tors, ER and others) to trigger a cascade of phosphorylation 
events and new protein–protein interactions in tumor cells 
and tumor endothelial cells, that allow the angiogenic and 
metastatic behavior of tumors. In fact, preclinical data 
with anti-Src and anti-FAK agents under development 
show that both types of inhibitors lead to antiproliferative, 
antiangiogenic and antimetastatic responses in human 
tumor models; a synergistic effect with other anticancer 
agents has been also observed. Therefore the inhibition 
of one of these kinases appears to be a successful thera-
peutic approach to avoid recurrence and dissemination of 
the primary tumor and also the progression of metastatic 
lesions.
Currently, we have robust data to believe FAK and c-Src 
inhibitors as a novel and promising anticancer strategy to 
combine with current anticancer therapies. A synergistic 
effect has already been shown when they are combined 
with other antitarget agents (ie, gefitinib, imatinib and 
  sunitinib). Furthermore, these drugs have also been shown 
to be good candidates in the avoidance of chemotherapy and 
  hormonotherapy resistances.
In addition, although it remains difficult to asses the 
efficacy of antimetastatic agents in the clinical setting, 
its appears that the inhibition of Src and FAK may have a 
potent anti-invasive effect, to delay tumor dissemination 
rather than real tumor shrinkage. Furthermore, although     
levels have already been seen as a possible predictor of 
response to Src inhibitors there is still a lack of suitable 
biomarkers that would be able to predict a response to these 
agents. In addition to current clinical studies of biomarker 
assays, the use of more sophisticated imaging technolo-
gies and the testing of the tumor, guided by biochemical 
rational, will help to maximize the development of these 
new compounds.
We have reviewed those trials with FAK and Src inhibitors 
under clinical development as a single agent or in combina-
tion with other therapeutic approaches. They have already 
shown clinical benefits in cancer patients with solid tumors. 
The identification of useful biomarkers to assess target inhi-
bition, anti-invasive efficacy and predict treatment response 
will be crucial for future clinical trials.
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